ORBCEL™ for Primary Sclerosing Cholangitis
Primary Sclerosing Cholangitis (PSC)
Pre-clinical/ResearchActive
Key Facts
Indication
Primary Sclerosing Cholangitis (PSC)
Phase
Pre-clinical/Research
Status
Active
Company
About Orbsen Therapeutics
Orbsen Therapeutics is a private, clinical-stage biotech developing immunomodulatory cell therapies for serious conditions with high unmet need, including Diabetic Kidney Disease (DKD) and Acute Respiratory Distress Syndrome (ARDS). Its lead candidate, ORBCEL™, is a purified MSC therapy designed to target specific immune pathways driving inflammation and fibrosis. The company has advanced ORBCEL™ into Phase 2 clinical trials, supported by significant non-dilutive EU grant funding, and is actively fundraising to progress its pipeline. Orbsen operates from a new headquarters in Galway, positioning itself at the forefront of next-generation cell therapy.
View full company profileTherapeutic Areas
Other Primary Sclerosing Cholangitis (PSC) Drugs
| Drug | Company | Phase |
|---|---|---|
| PRO-PSC-001 | ProdIgY Biotech | Discovery |
| 4P025 | 4P-Pharma | Discovery |
| Volixibat | Mirum Pharmaceuticals | Phase 2b |
| Elafibranor (GFT505) | Genfit | Phase 2 |
| Bexotegrast (PLN-74809) | Pliant Therapeutics | Phase 2a |